Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Mobile Software as a Medical Device (SaMD) for the Treatment of Epilepsy: Development of Digital Therapeutics Comprising Behavioral and Music-Based Interventions for Neurological Disorders.

Afra P, Bruggers CS, Sweney M, Fagatele L, Alavi F, Greenwald M, Huntsman M, Nguyen K, Jones JK, Shantz D, Bulaj G.

Front Hum Neurosci. 2018 May 1;12:171. doi: 10.3389/fnhum.2018.00171. eCollection 2018.

2.

A Prototype Exercise-Empowerment Mobile Video Game for Children With Cancer, and Its Usability Assessment: Developing Digital Empowerment Interventions for Pediatric Diseases.

Bruggers CS, Baranowski S, Beseris M, Leonard R, Long D, Schulte E, Shorter A, Stigner R, Mason CC, Bedrov A, Pascual I, Bulaj G.

Front Pediatr. 2018 Apr 9;6:69. doi: 10.3389/fped.2018.00069. eCollection 2018.

3.

Commentary: A Breathing-Based Meditation Intervention for Patients with Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study.

McKennon S, Levitt SE, Bulaj G.

Front Med (Lausanne). 2017 Apr 6;4:37. doi: 10.3389/fmed.2017.00037. eCollection 2017. No abstract available.

4.

The novel anticonvulsant neuropeptide and galanin analogue, NAX-5055, does not alter energy and amino acid metabolism in cultured brain cells.

Aldana BI, Waagepetersen HS, Schousboe A, White HS, Bulaj G, Walls AB.

J Neurosci Res. 2017 Nov;95(11):2286-2296. doi: 10.1002/jnr.24057. Epub 2017 Apr 11.

PMID:
28397993
5.

Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.

Metcalf CS, Smith MD, Klein BD, McDougle DR, Zhang L, Bulaj G.

Neurochem Res. 2017 Jul;42(7):1983-1994. doi: 10.1007/s11064-017-2229-5. Epub 2017 Apr 6.

6.

Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics.

Metcalf CS, Klein BD, McDougle DR, Zhang L, Kaufmann D, Bulaj G, White HS.

Epilepsia. 2017 Feb;58(2):239-246. doi: 10.1111/epi.13647. Epub 2017 Jan 18.

7.
8.
9.

The anticonvulsant action of the galanin receptor agonist NAX-5055 involves modulation of both excitatory- and inhibitory neurotransmission.

Walls AB, Flynn SP, West PJ, Müller MS, Bak LK, Bulaj G, Schousboe A, White HS.

Epilepsy Res. 2016 Mar;121:55-63. doi: 10.1016/j.eplepsyres.2016.01.006. Epub 2016 Jan 27.

PMID:
26894875
10.

Structural Basis for the Inhibition of Voltage-gated Sodium Channels by Conotoxin μO§-GVIIJ.

Green BR, Gajewiak J, Chhabra S, Skalicky JJ, Zhang MM, Rivier JE, Bulaj G, Olivera BM, Yoshikami D, Norton RS.

J Biol Chem. 2016 Mar 25;291(13):7205-20. doi: 10.1074/jbc.M115.697672. Epub 2016 Jan 27.

11.

Clinical and Neurobiological Perspectives of Empowering Pediatric Cancer Patients Using Videogames.

Govender M, Bowen RC, German ML, Bulaj G, Bruggers CS.

Games Health J. 2015 Oct;4(5):362-74. doi: 10.1089/g4h.2015.0014. Epub 2015 Jun 26.

12.

Probing the Redox States of Sodium Channel Cysteines at the Binding Site of μO§-Conotoxin GVIIJ.

Zhang MM, Gajewiak J, Azam L, Bulaj G, Olivera BM, Yoshikami D.

Biochemistry. 2015 Jun 30;54(25):3911-20. doi: 10.1021/acs.biochem.5b00390. Epub 2015 Jun 18.

PMID:
26039939
13.

A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties.

Lee HK, Zhang L, Smith MD, Walewska A, Vellore NA, Baron R, McIntosh JM, White HS, Olivera BM, Bulaj G.

Front Pharmacol. 2015 Feb 10;6:11. doi: 10.3389/fphar.2015.00011. eCollection 2015.

14.

Structure and function of μ-conotoxins, peptide-based sodium channel blockers with analgesic activity.

Green BR, Bulaj G, Norton RS.

Future Med Chem. 2014 Oct;6(15):1677-98. doi: 10.4155/fmc.14.107. Review.

15.

Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.

Metcalf CS, Klein BD, McDougle DR, Zhang L, Smith MD, Bulaj G, White HS.

J Pharmacol Exp Ther. 2015 Jan;352(1):185-93. doi: 10.1124/jpet.114.219063. Epub 2014 Oct 27.

16.
17.

Interactions of disulfide-deficient selenocysteine analogs of μ-conotoxin BuIIIB with the α-subunit of the voltage-gated sodium channel subtype 1.3.

Green BR, Zhang MM, Chhabra S, Robinson SD, Wilson MJ, Redding A, Olivera BM, Yoshikami D, Bulaj G, Norton RS.

FEBS J. 2014 Jul;281(13):2885-98. doi: 10.1111/febs.12835. Epub 2014 Jun 9.

18.

From molecular phylogeny towards differentiating pharmacology for NMDA receptor subtypes.

Platt RJ, Curtice KJ, Twede VD, Watkins M, Gruszczyński P, Bulaj G, Horvath MP, Olivera BM.

Toxicon. 2014 Apr;81:67-79. doi: 10.1016/j.toxicon.2014.01.016. Epub 2014 Feb 7.

19.

A disulfide tether stabilizes the block of sodium channels by the conotoxin μO§-GVIIJ.

Gajewiak J, Azam L, Imperial J, Walewska A, Green BR, Bandyopadhyay PK, Raghuraman S, Ueberheide B, Bern M, Zhou HM, Minassian NA, Hagan RH, Flinspach M, Liu Y, Bulaj G, Wickenden AD, Olivera BM, Yoshikami D, Zhang MM.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2758-63. doi: 10.1073/pnas.1324189111. Epub 2014 Feb 4.

20.

On the importance of oxidative folding in the evolution of conotoxins: cysteine codon preservation through gene duplication and adaptation.

Steiner AM, Bulaj G, Puillandre N.

PLoS One. 2013 Nov 11;8(11):e78456. doi: 10.1371/journal.pone.0078456. eCollection 2013.

Supplemental Content

Loading ...
Support Center